Premium
FDA approves Rexulti to treat schizophrenia and as an add‐on to an antidepressant to treat major depressive disorder
Publication year - 2015
Publication title -
the brown university child and adolescent psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7567
pISSN - 1527-8395
DOI - 10.1002/cpu.30069
Subject(s) - antidepressant , major depressive disorder , schizophrenia (object oriented programming) , food and drug administration , psychiatry , medicine , depressive symptoms , drug , psychology , pharmacology , anxiety , cognition
On July 10, the U.S. Food and Drug Administration approved Rexulti (brexpiprazole) tablets to treat adults with schizophrenia and as an add‐on treatment to an antidepressant medication to treat adults with major depressive disorder (MDD).